Ergoteles’s Cyclerion Therapeutics CYCN Stock Holding History

Ergoteles’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,805	Closed	-$375K	–	1305
2021 Q2	$375K	Buy	+4,805	New	+$301K	0.01%	952

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's CYCN Position: Q3 2021 in Review

Ergoteles sold out of Cyclerion Therapeutics (CYCN) in Q3 2021, closing a stake of 4,805 shares — an estimated $375K sold.

Ergoteles first reported a position in CYCN in Q2 2021 and held it in 1 quarter. The position peaked at $375K in Q2 2021. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

Ergoteles reported no remaining Cyclerion Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 4,805 Cyclerion Therapeutics shares in Q3 2021, an estimated $375K.
Ergoteles first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Cyclerion Therapeutics position peaked at $375K in Q2 2021.
61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.